A patient at a Rutherford Cancer Centre has become the first in the UK to receive a pioneering new treatment for prostate cancer, made possible through an industry-leading partnership between Rutherford Health and Panthera.
It is the first multisite oncology trial to be undertaken by the independent sector in the UK.
Clinicians are hoping the new drug therapy – which is also the first trial to take place at a Rutherford Cancer Centre – could increase survival benefits for patients with an advanced form of prostate cancer, known as metastatic castration-resistant cancer (mCRPC). It is believed that about 20% of patients with mCRPC possess the biomarker to be eligible for this new form of treatment, with current treatment options offering a limited duration of clinical and survival benefits.
The trial is part of a phase II study that will focus on determining the optimal dose of treatment for this potential new drug therapy. Phase one studies have been successfully carried out in countries outside of the UK.
Professor Karol Sikora, chief medical officer of Rutherford Health and consultant oncologist, said: “We are absolutely delighted to be hosting our very first trial here at our centre in the North East.
“It is very important that the UK grows its capacity to carry out oncology trials so that more patients have access to the latest treatments and that our world-leading oncologists are at the cutting edge of research. There is a global shortage of top-class oncology research sites with access to leading oncology experts and our partnership with Panthera and their expertise in running clinical trials will provide both.”
There are more than 75,000 oncology related trials underway across the world with the number growing rapidly.
A 71-year-old patient from Middlesbrough became the first person in the UK to receive this new drug. Starting the trial this week, he said: “I am grateful to have the opportunity to participate in this new trial and play a role in the development of potential new treatments for prostate cancer.”